CN107937538A - Glioma diagnosis marker circ1:201817088|201817285 and application - Google Patents
Glioma diagnosis marker circ1:201817088|201817285 and application Download PDFInfo
- Publication number
- CN107937538A CN107937538A CN201711454282.2A CN201711454282A CN107937538A CN 107937538 A CN107937538 A CN 107937538A CN 201711454282 A CN201711454282 A CN 201711454282A CN 107937538 A CN107937538 A CN 107937538A
- Authority
- CN
- China
- Prior art keywords
- glioma
- circ1
- diagnosis
- excretion body
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010018338 Glioma Diseases 0.000 title claims abstract description 38
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 32
- 238000003745 diagnosis Methods 0.000 title claims abstract description 25
- 239000003550 marker Substances 0.000 title claims abstract description 8
- 210000002966 serum Anatomy 0.000 claims abstract description 27
- 230000029142 excretion Effects 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 238000010839 reverse transcription Methods 0.000 claims description 7
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 abstract description 5
- 210000001808 exosome Anatomy 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108091028075 Circular RNA Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of biology, and discloses a glioma diagnosis marker circ1:201817088|201817285 and application thereof. In the present invention, the expression level of circ1:201817088|201817285 in the serum exosome of glioma patients was found to be significantly higher (P ═ 0.003) compared with the control group for the first time, and ROC analysis showed that it has higher diagnostic value for glioma (AUC ═ 0.937, P ═ 0.004, sensitivity and specificity of 85.7% and 88.9%, respectively). Therefore, by detecting the expression level of circ1:201817088|201817285 in the serum exosome of the glioma patient, the early and rapid noninvasive diagnosis of the glioma patient can be made.
Description
Technical field
The invention belongs to biological technical field, is related to a kind of serum circRNA markers for diagnosis of glioma
circ1:201817088 | 201817285 and detect the marker reagent be used to prepare the application of diagnosis of glioma preparation,
Also kit.
Background technology
Glioma is the brain tumor disease that adult takes place frequently the most, accounts for the 40.49% of intracranial tumors.Since making a definite diagnosis,
The Patients with gliomas the average survival time service life is no more than 5 years.For this evil high with inhereditary material correlation of diagnosis and treatment glioma
Property disease, it is necessary to it is horizontal in molecular biology, explore its pathogenesis in terms of hereditary information expression.Presently colloid
Though the diagnostic and therapeutic method of knurl is in and continuously improves the stage, patients with gliomas survival rate is not significantly improved.Colloid
Knurl diagnosis is still within the experience sexual stage based on clinical, pathology and iconography information, and one after diagnosing, absolutely mostly
Number is middle and advanced stage, and postoperative survival rate allows of no optimist.Therefore, diagnosis of glioma marker is found to sieve people at highest risk
Look into, and correspondingly select rational successive treatment scheme, improve survival rate, be neuroscience field Task urgently to be resolved hurrily.
Circular rna is a kind of extensive and is diversely present in mammalian cell, has controlling gene expressional function
Endogenous non-coding RNA molecule, has covalence closed loop configuration, is widely present in various cells, and after
The current research hot spot of microRNA (miRNA) RNA families afterwards.In recent years, with the extensive use and life of deep sequencing technology
The fast development of thing physics and informatics technology, it has been found that the transcript of many extrons of the mankind non-linearly can reversely be cut
Connect or circular rna is formed by gene rearrangement, and they account for sizable ratio in all montage transcripts.In recent years
Also gradually find also to contain substantial amounts of circular rna in excretion body, may play a significant role.Excretion body refers to contain complexity
The small film bubble (30-150nm) of RNA and protein, now, it refers in particular to plate-like vesica of the diameter in 40-100nm.Nineteen eighty-three, excretion
Body is found in sheep granulophilocyte first, and Johnstone is named as " exosome " within 1987.Research in recent years is shown
Show, excretion body is the important molecule of cell and cell-cell communication, participates in many physiology and pathologic process.Not only wrapped in excretion body
Containing protein component, further include some RNA components, as Microrna (micro RNA, miRNA), long-chain non-coding RNA and
MRNA, circular rna (circular RNA, circRNA).These RNA entrained by excretion body are referred to as excretion body source RNA,
With complete sequential structure and bioactivity, it is expected to, as liquid biopsy molecular marker, on accurate medical development have
Bright prospect.
The content of the invention
The present invention first purpose be:A kind of serum excretion body circRNA markers for diagnosis of glioma are provided.
Main contents include:A kind of serum excretion body circRNA markers circ1 for diagnosis of glioma:
201817088 | 201817285, its sequence such as SEQ NO:Shown in 1.The circRNA is located on No. 1 chromosome of the mankind, entirely
Long 198bp.
Second object of the present invention is to provide detection circRNA markers expression quantity in serum excretion body
Application of the reagent in diagnosis of glioma preparation is prepared.
Third object of the present invention is to provide a kind of diagnosis of glioma kit, it can be measured in serum excretion body
Circ1:201817088 | 201817285 content.
The diagnosis of glioma kit, contains detection circ1:201817088 | the PCR of 201817285 contents draws
Thing.It is preferred that the sequence of primer such as SEQ NO:Shown in 2 and 3.
The diagnosis of glioma kit, except circ1:201817088 | outside 201817285 primer, also contain from blood
Excretion body is extracted in clear, by extracting RNA in excretion body and carrying out all reagents of reverse transcription and quantitative fluorescent PCR.
Including:
(1) reagent needed for serum excretion body is extracted:Total Exosome Isolation Reagent(from
Serum), can be bought by Invitrogen companies, article No. 4478360;
(2) reagent needed for excretion body RNA is extracted:Trizol reagents, chloroform, isopropanol, 75% ethanol, without enzyme water;
(3) reagent needed for reverse transcription:Random primer (Random Primer), without enzyme water, 5 × RT Buffer, three phosphorus
Soda acid base deoxynucleotide, RNase inhibitor, MMLV reverse transcriptases;
(4) reagent needed for quantitative fluorescent PCR:circ1:201817088 | 201817285 upstream and downstream primers, GAPDH internal references
Upstream and downstream primer, SYBR dyestuffs, without enzyme water.
The beneficial effects of the present invention are:
Circ1 in the serum excretion body of patients with gliomas is found first:201817088 | 201817285 compare normal serum
Excretion body is according to group significantly up-regulation (p=0.003).ROC curve is analysis shows that circ1:201817088 | 201817285 as biology
Label has glioma higher diagnostic value, and (AUC=0.937, sensitivity and specificity are respectively 85.7% He
88.9%).By application of the circular rna in diagnosis of glioma analysis, it can cause the more convenient standard of diagnosis of glioma
Really, conditions of patients is quick and precisely grasped for clinician, laid the foundation to improve clinical therapeutic efficacy, and it is potential to find to have
The new small molecule drug targets of therapeutic value provide help.
Brief description of the drawings
Fig. 1 analyzes circ1 for real-time fluorescence quantitative PCR:201817088 | 201817285 patients with gliomas serum with just
Differential expression in normal serum excretion body;
Fig. 2 is the circ1 that Roc analyzes serum excretion body source:201817088 | 201817285 pairs of glioma early diagnosis
Specificity, sensitivity.
Embodiment
The present invention is intended to further illustrate below in conjunction with embodiment, is not intended to limit the present invention.
First, research object
The serum sample of 40 patients with gliomas is provided by Xiang Ya hospitals, and 15 normal serum samples carry out community for the same period
The healthy individuals of disorder in screening.Sample for research is collected for the same period, sample, dispense, preservation condition it is consistent.
2nd, research method
1. the extracting of RNA in glioma/normal serum excretion body
Take 200 μ l of serum to be centrifuged 30 minutes in 2000g room temperature, supernatant liquor is extracted to 600 new μ l with micropipettor
Centrifuge tube, adds 40 μ l excretion bodies extracts reagent (Total Exosome Isolation Reagent (from serum), goods
Number 4478360, Invitrogen companies) gently turning upside down shakes up, and 4 DEG C are incubated 45 minutes.10000g room temperature after incubation
Centrifugation 10 minutes, discards supernatant, and gained precipitation is the excretion body in serum.200 μ l Trizol (MRC are added in precipitation
Company) precipitation is resuspended, suspension is moved to new 1.5ml tube manages, and mends Trizol to 1ml.15min is cracked on ice.Cracking knot
4 DEG C after beam, 12000rpm centrifugation 10min, supernatant moves to new tube pipes.Chlorination imitates 200 μ l in Tube, is shaken with hand
15-30s, places 5min, 4 DEG C, 12000rpm centrifuges 15min on ice;Carefully take upper strata aqueous phase to enter in new tube, add precooling
Isopropanol 0.5ml is mixed, and stands be more than 20min on ice, 4 DEG C, 12000rpm centrifugations 10min;Supernatant is abandoned, adds 75%DEPC water
Diluted ethanol 1ml is mixed, 4 DEG C, and 7500rpm centrifugation 5min, abandon supernatant, drying at room temperature 5-10min, adds no enzyme water 10 as far as possible
μ l dissolve RNA.- 80 DEG C of preservations, refrigerator temperature is recorded by laboratory technician daily.It is prepared by 2.cDNA
Reverse transcription reaction is carried out according to Reverse Transcriptase kit (Thermo companies) specification.Reaction cumulative volume is (total for 20 μ l
RNA10 μ l, Random primer 1 μ l, no 1 μ l, 5 × Reaction Buffer of enzyme water 4 μ l, RI 1 μ l, RT 1 μ l and
10mM dNTP 2μl)。
Component | Dosage/pipe |
Random reverse transcriptase primer (1 μM) | 1μl |
RNA samples | 10μl |
Without enzyme water | To 12μl |
Reverse transcription first step condition:65 DEG C 5 minutes
Reverse transcription second step program:25 DEG C 5 minutes, 42 DEG C 60 minutes, 70 DEG C 5 minutes.
3. real-time fluorescence quantitative PCR
(primer sequence is shown in SEQ NO to the specific primer synthesized using Han Heng biotechnologies (Shanghai) Co., Ltd.:2 and 3)
Carry out real-time quantitative PCR:Reverse transcription product is first diluted 10 times, is mixed.20 μ l reaction systems are as follows:
Component | Dosage/pipe |
SYBR Premix Ex Taq | 10μl |
Primer (10 μM) | 0.5μl |
CDNA products (after dilution) | 5μl |
Without enzyme water | To 20μl |
Real-time fluorescence quantitative PCR response procedures:95 DEG C 3 minutes, 40 circulation, 95 DEG C 10 seconds, 60 DEG C 30 seconds.
4. data analysis:Using 2-ΔΔCTRepresent the circ1 of glioma serum excretion body:201817088 | 201817285 phases
For the expression multiple of normal serum excretion body, wherein △ CT=CTSample–CTInternal reference, Δ Δ CT=Δs CTGlioma–ΔCTNormally.This reality
The analysis method that data use relative quantification is tested, (primer sequence is shown in SEQ NO to GAPDH as reference gene:4 and 5), data profit
Analyzed with software GraphPad Prism and SPSS 17.0.
3rd, result of study
1. the serum excretion body of patients with gliomas is to circ1:201817088 | 201817285 have obvious enrichment, and phase
Up-regulation (p=0.003) more notable than normal serum excretion body control group, specific data are as shown in Figure 1.
2.ROC tracing analysis shows circ1:201817088 | 201817285 have glioma as biomarker
(AUC=0.937, sensitivity and specificity are respectively 85.7% and 88.9%), and detailed results are shown in Fig. 2 for higher diagnostic value.
Sequence table
<110>Xiangya Hospital, Central-South China Univ.
<120>Diagnosis of glioma marker circ1:201817088 | 201817285 and application
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 198
<212> RNA
<213>Homo sapiens (Homo sapiens)
<400> 1
guccauggac agaaagcugc uugggaggac ccaguggaau ggguccggga cacacuuccc 60
uggccaucag cccaacaaga ccaaucaaag cuguaccacc ugcccccacc caccgugggc 120
ccucacagca uugccucacc ucccgaggau aggacaguca aagacagcac cccaaguucu 180
cuggacucag auccucug 198
<210> 2
<211> 18
<212> DNA
<213>Unknown (Unknown)
<400> 2
cacagcattg cctcacct 18
<210> 3
<211> 18
<212> DNA
<213>Unknown (Unknown)
<400> 3
cctcccaagc agctttct 18
<210> 4
<211> 19
<212> DNA
<213>Unknown (Unknown)
<400> 4
atcatcagca atgcctcct 19
<210> 5
<211> 18
<212> DNA
<213>Unknown (Unknown)
<400> 5
catcacgcca cagtttcc 18
Claims (6)
- A kind of 1. diagnosis of glioma marker circ1:201817088 | 201817285, its sequence such as SEQ NO:Shown in 1.
- 2. the reagent of marker expression quantity in serum excretion body described in test right requirement 1 is preparing diagnosis of glioma preparation In application.
- 3. a kind of diagnosis of glioma kit, it is characterised in that the circ1 in serum excretion body can be measured:201817088| 201817285 content.
- 4. diagnosis of glioma kit according to claim 3, it is characterised in that contain detection circ1:201817088| The PCR primer of 201817285 contents.
- 5. diagnosis of glioma kit according to claim 4, it is characterised in that the sequence of primer such as SEQ NO:2 and 3 It is shown.
- 6. according to the diagnosis of glioma kit described in claim 3 or 4 or 5, it is characterised in that except circ1:201817088| Outside 201817285 primer, also contain and excretion body is extracted from serum, by extracting RNA in excretion body and carrying out reverse transcription and glimmering All reagents of Fluorescent Quantitative PCR.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711454282.2A CN107937538B (en) | 2017-12-28 | 2017-12-28 | Glioma diagnosis marker circ1:201817088|201817285 and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711454282.2A CN107937538B (en) | 2017-12-28 | 2017-12-28 | Glioma diagnosis marker circ1:201817088|201817285 and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107937538A true CN107937538A (en) | 2018-04-20 |
CN107937538B CN107937538B (en) | 2020-06-30 |
Family
ID=61940619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711454282.2A Expired - Fee Related CN107937538B (en) | 2017-12-28 | 2017-12-28 | Glioma diagnosis marker circ1:201817088|201817285 and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107937538B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110205320B (en) * | 2019-06-18 | 2023-06-23 | 中国医科大学附属盛京医院 | lncRNA molecule linc00998 and application thereof in glioma treatment/prognosis evaluation |
-
2017
- 2017-12-28 CN CN201711454282.2A patent/CN107937538B/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
RYBAK-WOLF ET AL.: "Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed.", 《MOLECULAR CELL》 * |
SALZMAN ET AL.: "Cell-Type Specific Features of Circular RNA Expression.", 《PLOS GENETICS》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110205320B (en) * | 2019-06-18 | 2023-06-23 | 中国医科大学附属盛京医院 | lncRNA molecule linc00998 and application thereof in glioma treatment/prognosis evaluation |
Also Published As
Publication number | Publication date |
---|---|
CN107937538B (en) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9868988B2 (en) | Method to assess human allograft status from microrna expression levels | |
CN107937532A (en) | Glioma diagnosis marker hsa _ circ _0021827 and application | |
CN107557472A (en) | Glioma diagnosis marker circ9:135881633|135883078 and application | |
CN107937538A (en) | Glioma diagnosis marker circ1:201817088|201817285 and application | |
CN106244688A (en) | A kind of mark assessing adenocarcinoma of colon risk | |
CN107586843A (en) | Glioma diagnosis marker circ7:100812747|100813208 and application | |
CN109536502A (en) | A kind of PCR internal reference suitable for Trophoblastic Tumor blood plasma excretion body miRNA | |
CN107619869A (en) | Glioma diagnosis and prognosis marker circ16:85633914|85634132 and application | |
CN107586846A (en) | Glioma diagnosis marker Circ3:129880309|129880559 and application | |
CN107604076A (en) | Glioma diagnosis marker Circ6:4891713|4892379 and application | |
CN107937534A (en) | Glioma diagnosis marker circ1:29154696|29154910 and application | |
CN107586844A (en) | Application of glioma prognostic marker Circ9:135881633|135883078 | |
CN107937540A (en) | Glioma diagnosis marker circ17:47618350|47619164 and application | |
CN107937529A (en) | Glioma diagnosis marker hsa _ circ _0135404 and application | |
CN107557441B (en) | Glioma diagnosis marker Circ2:23823258|23823569 and application | |
CN107586845A (en) | Glioma diagnosis marker Circ19:5604583|5604936 and application | |
CN107937543A (en) | Glioma diagnosis marker circ10:72715111|72715902 and application | |
CN107937528A (en) | Glioma prognosis marker hsa _ circ _0125365 and application | |
CN107586849A (en) | Application of circ9:4117768|4118881 derived from brain tissue | |
CN107604073A (en) | Glioma diagnosis marker circ22:42890947|42891182 and application | |
CN107937527A (en) | Glioma diagnosis marker circ1:43920404|43920928 and application | |
CN107988368A (en) | Glioma diagnosis marker circ9:33948374|33948587 and application | |
CN107557474A (en) | Glioma diagnosis marker circ15:98707562|98708107 and application | |
CN107937531A (en) | Glioma diagnosis marker circ7:73686636|73687095 and application | |
CN107604070A (en) | Glioma diagnosis marker circ9:4117768|4118881 and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200630 |
|
CF01 | Termination of patent right due to non-payment of annual fee |